Medscape5 天
FDA Okays New Rapid-Acting Biosimilar Insulin for Diabetes
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...
U.S. News & World Report3 天
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes By Stephanie Brown HealthDay Reporter WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug ...
MedPage Today9 天
FDA OKs First Rapid-Acting Insulin Biosimilar for Diabetes
Opens in a new tab or window The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and children with diabetes, the agency announced ...
WebMD2 天
FDA OKs First Fast-Acting Insulin Biosimilar for Diabetes
With more people needing daily insulin, biosimilar options can make this lifesaving treatment more accessible. Merilog, made by Sanofi-Aventis, is a rapid-acting insulin biosimilar (similar to ...
Finanznachrichten6 天
FDA Approves Merilog Rapid-Acting Insulin Biosimilar For Diabetes
PARIS (dpa-AFX) - The U.S. Food and Drug Administration announced that Sanofi-Aventis U.S. LLC's Merilog (insulin-aspart-szjj) becomes the first rapid-acting insulin biosimilar product to get its ...
Yahoo Finance8 天
FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes
Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Merilog helps to lower mealtime blood sugar ...
Benzinga.com5 天
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Merilog is available in a 3 mL prefilled pen and a 10 mL vial, joining two long-acting insulin biosimilars approved by the FDA in 2021. Merilog, a rapid-acting human insulin analog, is the first ...